financetom
Business
financetom
/
Business
/
AbbVie's ovarian cancer therapy succeeds in mid-stage trial
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
AbbVie's ovarian cancer therapy succeeds in mid-stage trial
Jun 6, 2024 6:04 AM

June 6 (Reuters) - AbbVie ( ABBV ) said on Thursday its

therapy to treat patients with a type of ovarian cancer has met

the main goal of a mid-stage trial.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Kadant Receives $18 Million in Orders for Wood Processing Systems
Kadant Receives $18 Million in Orders for Wood Processing Systems
May 28, 2025
05:18 PM EDT, 05/28/2025 (MT Newswires) -- Kadant ( KAI ) said Wednesday that it received orders for wood processing systems from three lumber producers in North America and Europe for a combined value of $18 million. The capital equipment orders will be shipped between end of the year and Q3 2026, according to Kadant ( KAI ). The equipment...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Amer Sports Starts Secondary Offering of 35 Million Shares
Amer Sports Starts Secondary Offering of 35 Million Shares
May 28, 2025
05:14 PM EDT, 05/28/2025 (MT Newswires) -- Amer Sports ( AS ) started a registered secondary offering of 35 million shares by entities affiliated with FountainVest Partners. Amer Sports ( AS ) isn't selling any shares and won't receive any proceeds from the offering. The offering is subject to market conditions, Amer Sports ( AS ) said Wednesday in a...
Neurocrine Reports Positive Data in Mid-Stage Schizophrenia Trial
Neurocrine Reports Positive Data in Mid-Stage Schizophrenia Trial
May 28, 2025
05:15 PM EDT, 05/28/2025 (MT Newswires) -- Neurocrine Biosciences ( NBIX ) said Wednesday its NBI-1117568 drug candidate to treat schizophrenia showed a significant improvement in symptoms and overall severity in a phase 2 trial. This compound is promising as it is a direct and selective muscarinic M4 receptor agonist, which is believed to be a key regulator of neurotransmitters...
Copyright 2023-2026 - www.financetom.com All Rights Reserved